JW Creagene, a subsidiary of JW Shinyak, said that it has registered a patent in Europe and Japan for its source technology to produce dendritic cells and how to use them.
The patent registrations came after the company obtained a similar patent in Korea in 2015 and the United States in 2019.
Dendritic cells direct T cells, which are in charge of immunity function within the body, to attack specific cells, such as cancer cells. They can be developed into various treatments depending on antigens.
In Europe, the company plans to acquire individual patents for key European countries in the first half of the year.
The company has developed a cytoplasmic transduction peptide that effectively delivers antigens to dendritic cells, which is one of the autoimmune cells, and has developed CreaVax, an immune cell therapy product using this method.
Using this treatment, the company is conducting a phase 3 clinical trial for liver cancer using CreaVax-HCC and phase 1/2 clinical trials for glioblastoma (CreaVax-BC).
“Our company has won the confirmation for our unique technology and rights through our global patent strategy,” JW Creagene CEO Lee Kyung-joon said. “We will continue to secure competitiveness in the next-generation anticancer drug market by adding value to our patents, through successful commercialization and technology transfer.”
<© Korea Biomedical Review, All rights reserved.>